Oncotype IQ® Portfolio of Tests
Every cancer is unique and affects each diagnosed person differently based on the individual biology of their disease. To address this diversity and make cancer care smarter at every stage, our Oncotype IQ diagnostic tests and services portfolio delivers clinically relevant genomic intelligence that reveals the individual biology of a patient's tumor. This additional genomic insight helps physicians optimize treatment decisions for breast, colon, and prostate cancers.
In addition to the Oncotype DX suite of tests, the Oncotype IQ portfolio now includes a comprehensive genomic profiling panel to bring fast and informative answers to patients with advanced, metastatic, refractory, or recurrent cancer. The Oncotype MAPTM Pan-Cancer Tissue test provides rapid tumor profiling for advanced cancer patients, giving physicians confidence to deliver fast answers patients need when there is no time to wait. It allows physicians to understand a patient’s tumor profile and recommend targeted therapies or clinical trials, with fast turnaround time1,2 and small samples3.